OBJECTIVE-Activating mutations in the KCNJ11 and ABCC8 genes encoding the Kir6.2 and SUR1 subunits of the pancreatic ATP-sensitive K ϩ channel are the most common cause of permanent neonatal diabetes. In contrast to KCNJ11, where only dominant heterozygous mutations have been identified, recessively acting ABCC8 mutations have recently been found in some patients with neonatal diabetes. These genes are co-located on chromosome 11p15.1, centromeric to the imprinted BeckwithWiedemann syndrome (BWS) locus at 11p15.5. We investigated a male with hemihypertrophy, a condition classically associated with neonatal hyperinsulinemia and hypoglycemia, who developed neonatal diabetes at age 5 weeks.
N
eonatal diabetes is a rare condition of hyperglycemia usually presenting during infancy or soon thereafter (1) . Etiologies other than autoimmunity are far more prevalent if diabetes is diagnosed before the age of 6 months (2). Recent developments have highlighted the importance of ion channel mutations ("channelopathies") in the etiology of both permanent and transient forms of this condition (3) (4) (5) . The pancreatic ␤-cell ATP-sensitive K ϩ channel (K ATP channel) is composed of four inward rectifying K ϩ channel (Kir6.2) subunits, encoded by the gene KCNJ11, and four sulfonylurea receptor (SUR1) subunits encoded by ABCC8. Its role is to control insulin release in response to glucose metabolism within the ␤-cell, through alterations in adenine nucleotide availability and binding (6) . Inactivating mutations in either KCNJ11 or ABCC8 cause persistent hyperinsulinemic hypoglycemia of infancy (7, 8) . Recently, Gloyn and colleagues described activating mutations in KCNJ11 as the cause of many cases of permanent (9) and a few cases of transient (10) neonatal diabetes; this has been confirmed in a large follow-up series (5, 11) . The mutant K ATP channels display reduced sensitivity to ATP-induced closure, thus preventing both membrane depolarization and insulin release in response to glucose. Clinically, it has been demonstrated that many, but not all, children affected by mutations in KCNJ11 can replace insulin therapy with high-dose oral sulfonylureas, usually glyburide (known in the U.K. as glibenclamide) (12) .
Activating mutations in the ABCC8 gene have also been linked to neonatal diabetes (3) (4) (5) (13) (14) (15) . Mutations may result in either a transient or permanent form of the disease. Like the KCNJ11 mutations, they cause the K ATP channel to remain open even when ATP is elevated by glucose metabolism. Clinically, neonatal diabetes due to ABCC8 mutations can also be abrogated through the therapeutic use of sulfonylureas (3, 4) .
Hemihypertrophy describes asymmetric overgrowth of part or half of the body. It may be isolated or part of the Beckwith-Wiedemann syndrome (BWS), a condition characterized by macroglossia, abdominal wall defects, neonatal hyperinsulinemia, and increased risk of embryonal tumors (16) . Both isolated hemihypertrophy and BWS can be caused by mosaic paternal uniparental isodisomy of chromosome 11p15 (17, 18) .
RESEARCH DESIGN AND METHODS
A male child weighing 3.87 kg at 40 weeks gestation (75th percentile) was born to nonconsanguineous, Somali parents. There had been two previous uneventful pregnancies. The proband was discharged home on the day of birth but returned to hospital aged 36 days, failing to thrive, severely dehydrated, and acidotic (pH 6.99 [normal range {NR} 7.3-7.4]). The initial blood glucose measured was 50 mmol/l with a bicarbonate of 5 mmol/l (NR 21-34) and urinary ketones of Ͼ160 mg/dl. A diagnosis of neonatal diabetes was made, and subsequent to resuscitation the child was stabilized on twice-daily subcutaneous insulin. Both parents had normal fasting glucose levels (father 5.2 mmol/l, age 36 years; mother 4.6 mmol/l, age 31 years) and no prior history of diabetes.
The child had left hemihypertrophy ( Fig. 1 ) but no macroglossia, anterior abdominal wall defects, ear creases, or peri-auricular pits as seen in BWS. Echocardiography of the heart revealed branch pulmonary artery stenosis but no cardiomegaly, while serial abdominal ultrasounds identified increasing left renal hypertrophy compared with a normal right kidney. Investigations. The young age of the patient at presentation suggested a diagnosis of neonatal diabetes. Blood was collected for DNA analysis of chromosome 6 anomalies causing transient neonatal diabetes (19) and for KCNJ11 mutation analysis (which at this time was the only channelopathy described as causing permanent neonatal diabetes). These tests were both normal. GAD, insulin, and islet cell autoantibodies were all negative. The child's karyotype was normal: 46 XY. However, microsatellite analysis of chromosome 11 revealed the child to be mosaic for paternal uniparental isodisomy (UPD) of 11pter-11p14 (Table 1 and Fig. 2A ). As neonatal diabetes is not characteristic of either BWS or isolated hemihypertrophy, this prompted a review of potential candidate genes for diabetes that were encompassed within this region of UPD. The SUR1 gene (ABCC8), which lies within this region, was a logical candidate, as it coassembles with Kir6.2 (KCNJ11) to form the K ATP channel, and activating mutations in KCNJ11 are known to cause neonatal diabetes (9 -11) .
The ABCC8 gene was sequenced as described previously (14) . The father was identified as being heterozygous for a missense mutation, N72S (c.215AϾG), while the proband's leukocyte DNA showed mosaicism for the N72S mutation (Fig. 2B) . The N72S mutation was not found in 250 normal chromosomes, and the affected residue was conserved across species. Quantification by real-time PCR (TaqMan assay) demonstrated that the N72S mutation was present at ϳ70% in leukocyte DNA and 50% in buccal cells. Briefly, genomic DNA from leukocytes and buccal cells was amplified using a mutation-specific TaqMan approach. Genomic DNA from the father, who is heterozygous for the N72S mutation, was used in serial dilution to produce standard curves to determine linear range and accuracy of quantification (primer and probe sequences are available on request). Reactions contained 5 l TaqMan Fast Universal PCR Mastermix without Amperase, 0.5 l Assaysby-Design (Applied Biosystems, Warrington, U.K.) probe and primer mix (corresponding to 36 l of each primer and 8 l of each probe), 2.5 l water, and 2 l DNA at a concentration of 100 ng/l. Amplification conditions consisted of a single cycle of 95°C for 20 s followed by 40 cycles of 95°C for 1 s and 60°C for 20 s. The relative level of mutant transcript relative to wild-type transcript was determined by the ⌬⌬CT method (20) . Each test was carried out in triplicate.
Functional studies in Xenopus oocytes (methods in 9,10) demonstrated that the N72S mutation results in a reduced sensitivity to inhibition by MgATP. Half-maximal block of homozygous N72S channels was produced by 23 Ϯ 1 mol/l ATP (n ϭ 10) compared with 15 Ϯ 1 mol/l (n ϭ 6) for wild-type channels. Two-electrode voltage-clamp studies showed a concomitant small increase in the whole-cell K ATP channel resting current (14) (Fig. 3) . Homozygous N72S channels were substantially blocked by the sulfonylurea tolbutamide in vitro (Fig. 3) .
Identification of an ABCC8 mutation, together with the patient's relatively poor control on twice-daily insulin (GHb 8.3% NR 4.0 -6.0%), the known Microsatellite analysis was performed according to standard methods with the primer sets listed in the Table. After 28 cycles of PCR, amplimers were resolved on an ABI 3100 platform and maternal and paternal allele levels compared in DNA from blood and buccal samples of the proband. The bold figures indicate alleles present at unexpectedly high dosage. Microsatellites D11STH and D11S1318 lie within the BWS region, while D11S921 and D11S902 bracket KCNJ11 and ABCC8.
efficacy of sulfonylureas in neonatal diabetes caused by K ATP channel mutations (21) , and the tolbutamide block of mutant N72S channels observed in functional studies, prompted a trial of the sulfonylurea glyburide. Over a 2-week period, under intensive monitoring in the hospital, regular subcutaneous insulin was withdrawn and glyburide gradually increased from a starting dose of 0.1 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 to a maximum dose of 1 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 . The therapeutic trial was terminated at 2 weeks due to the complete absence of a clinical response, with high blood glucose levels (up to 40 mmol/l) requiring the repeated administration of short-acting insulin to improve glycemia and prevent metabolic decompensation. The C-peptide level before initiating glyburide was Ͻ94 pmol/l and remained at Ͻ94 pmol/l on 1 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 glyburide. The child is now over 18 months of age and is treated with a basal bolus insulin regimen of four injections daily (ϳ1 unit ⅐ kg Ϫ1 ⅐ day Ϫ1 ) to maintain growth and health (recent A1C 6.6%). Although his neurological development at this stage seems normal, he remains under regular surveillance both for neurocognitive development and for increased tumor risk.
DISCUSSION
Uniparental isodisomy is a rare abnormality that provides insights into the genetic basis of human disease. Its identification in two cases of transient neonatal diabetes (22) led to identification of imprinting anomalies associated with the transient form of this condition. UPD can also unmask genetic disorders with an autosomal recessive pattern of inheritance (23) . In this case, the child's hemihypertrophy and relatively high birth weight (75th centile) did not fit with a diagnosis of permanent neonatal diabetes as, if anything, these features would be expected to co-segregate with hypoglycemia secondary to hyperinsulinemia (as seen in BWS). Since UPD can unmask recessive disorders, SUR1 (ABCC8) was an obvious candidate, due to its position within the disomic region of interest, its importance in insulin secretion, and the fact that focal adenomatous hyperplasia of islet cells with congenital hyperinsulinemia has been described in which loss of maternal 11p15 is associated with homozygosity of an ABCC8 mutation inherited from a heterozygous father (24) .
Recent studies have identified activating mutations in ABCC8 as causing both transient and permanent neonatal diabetes (3) (4) (5) . Several cases of permanent neonatal diabetes responded to glyburide at doses ranging from 0.22 to 0.59 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 (3), including one child with a dominant ABCC8 mutation (15) and at least four children with recessively inherited ABCC8 mutations (A.T. Hattersley, S.E.F., S.E., unpublished observations). Unfortunately, the child reported here was unresponsive to glyburide at a dose of as much as 1 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 . The complete absence of any clinical response in our infant prompted our withdrawal of glyburide after a 2-week trial, although a further trial when the child is older may be warranted given the in vitro response. The lack of a therapeutic response to sulfonyureas in our patient is puzzling, as the mutant N72S channels were blocked by tolbutamide in in vitro studies. It is possible that other imprinted genes involved in the paternal UPD might confer a reduced response.
In conclusion, we report a patient with UPD of chromosome 11 who presented with neonatal diabetes as opposed to the classical phenotype of hypoglycemia due to hyperinsulinemia. Paternal UPD of chromosome 11pter-11p14, encompassing the K ATP channel genes and the BWS locus, unmasked a recessively acting gain-of-function ABCC8 gene mutation, thus causing diabetes in addition to features of BWS. As has previously been described, the heterozygous father has no history of glucose intolerance or evidence of diabetes in adult life, as this is a recessively acting mutation (14) . The level of mosaicism for the N72S mutation varied between leukocytes (ϳ70% mutation) and buccal cells (ϳ50% mutation). As the child is alive and well, the mutation load within the pancreas remains unknown. Given the evidence that children with UPD11 can have highly variable levels of mosaicism in different organs, we hypothesize that the pancreas must exhibit a high level of paternal UPD cells to present with this phenotype, the somatic recombination causing the paternal UPD occurring very early during embryogenesis (25) .
We have recently identified nine other patients with recessively inherited ABCC8 mutations causing neonatal diabetes (14) .
